These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

491 related items for PubMed ID: 22562973

  • 1. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study.
    Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS.
    Ann Rheum Dis; 2013 Jan; 72(1):64-71. PubMed ID: 22562973
    [Abstract] [Full Text] [Related]

  • 2. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR.
    Ann Rheum Dis; 2013 Jun; 72(6):844-50. PubMed ID: 22739990
    [Abstract] [Full Text] [Related]

  • 3. Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.
    Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A.
    Lancet; 2014 Jan 25; 383(9914):321-32. PubMed ID: 24168956
    [Abstract] [Full Text] [Related]

  • 4. Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.
    Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.
    Ann Rheum Dis; 2014 Mar 25; 73(3):536-43. PubMed ID: 23316080
    [Abstract] [Full Text] [Related]

  • 5. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
    Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW.
    Ann Rheum Dis; 2013 Jan 25; 72(1):43-50. PubMed ID: 22562983
    [Abstract] [Full Text] [Related]

  • 6. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.
    Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH.
    J Rheumatol; 2009 Jul 25; 36(7):1429-41. PubMed ID: 19369462
    [Abstract] [Full Text] [Related]

  • 7. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK.
    Arthritis Rheum; 2004 May 25; 50(5):1400-11. PubMed ID: 15146409
    [Abstract] [Full Text] [Related]

  • 8. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.
    Smolen JS, Burmester GR, Combe B, Curtis JR, Hall S, Haraoui B, van Vollenhoven R, Cioffi C, Ecoffet C, Gervitz L, Ionescu L, Peterson L, Fleischmann R.
    Lancet; 2016 Dec 03; 388(10061):2763-2774. PubMed ID: 27863807
    [Abstract] [Full Text] [Related]

  • 9. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.
    Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT.
    Arthritis Rheum; 2006 Jan 03; 54(1):26-37. PubMed ID: 16385520
    [Abstract] [Full Text] [Related]

  • 10. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.
    Emery P, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Arendt C, Mountian I, Purcaru O, Tatla D, VanLunen B, Weinblatt ME.
    Ann Rheum Dis; 2017 Jan 03; 76(1):96-104. PubMed ID: 27165179
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR.
    Mazurov VI, Nasonov EL, Lila AM, Korolev MA, Prystrom AM, Kundzer EV, Soroka NF, Kastanayan AA, Povarova TV, Plaksina TV, Antipova OV, Krechikova DG, Smakotina SA, Tciupa OA, Puntus EV, Raskina TA, Shilova LN, Kropotina TV, Nesmeyanova OB, Popova TA, Vinogradova IB, Dokukina EA, Plotnikova AV, Pukhtinskaia PS, Zinkina-Orikhan AV, Linkova YN, Eremeeva AV, Lutckii AA.
    Dokl Biochem Biophys; 2024 Oct 03; 518(1):403-416. PubMed ID: 39196526
    [Abstract] [Full Text] [Related]

  • 12. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-year results of PREMIER.
    van der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewé R, Patra K, Pangan AL.
    J Rheumatol; 2010 Nov 03; 37(11):2237-46. PubMed ID: 20889601
    [Abstract] [Full Text] [Related]

  • 13. Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.
    Tanaka Y, Yamanaka H, Ishiguro N, Miyasaka N, Kawana K, Kimura J, Agata N, Takeuchi T.
    Arthritis Res Ther; 2017 Mar 14; 19(1):56. PubMed ID: 28288682
    [Abstract] [Full Text] [Related]

  • 14. Clinical, functional, and radiographic implications of time to treatment response in patients with early rheumatoid arthritis: a posthoc analysis of the PREMIER study.
    Keystone EC, Haraoui B, Guérette B, Mozaffarian N, Liu S, Kavanaugh A.
    J Rheumatol; 2014 Feb 14; 41(2):235-43. PubMed ID: 24293583
    [Abstract] [Full Text] [Related]

  • 15. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
    Yamanaka H, Ishiguro N, Takeuchi T, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.
    Rheumatology (Oxford); 2014 May 14; 53(5):904-13. PubMed ID: 24441150
    [Abstract] [Full Text] [Related]

  • 16. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T.
    Ann Rheum Dis; 2016 Jan 14; 75(1):75-83. PubMed ID: 26139005
    [Abstract] [Full Text] [Related]

  • 17. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.
    J Rheumatol; 2011 Nov 14; 38(11):2362-8. PubMed ID: 21885491
    [Abstract] [Full Text] [Related]

  • 18. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK.
    Arthritis Rheum; 2003 Jan 14; 48(1):35-45. PubMed ID: 12528101
    [Abstract] [Full Text] [Related]

  • 19. Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methotrexate (MTX)-naive patients with Early Erosive rheumatoid arthritis (AGREE).
    Smolen JS, Wollenhaupt J, Gomez-Reino JJ, Grassi W, Gaillez C, Poncet C, Le Bars M, Westhovens R.
    Arthritis Res Ther; 2015 Jun 11; 17(1):157. PubMed ID: 26063454
    [Abstract] [Full Text] [Related]

  • 20. Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.
    Kavanaugh A, van Vollenhoven RF, Fleischmann R, Emery P, Sainsbury I, Florentinus S, Chen S, Guérette B, Kupper H, Smolen JS.
    Ann Rheum Dis; 2018 Feb 11; 77(2):289-292. PubMed ID: 29146743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.